AU2018363292A1 - Molecules that bind to CD137 and PSMA - Google Patents

Molecules that bind to CD137 and PSMA Download PDF

Info

Publication number
AU2018363292A1
AU2018363292A1 AU2018363292A AU2018363292A AU2018363292A1 AU 2018363292 A1 AU2018363292 A1 AU 2018363292A1 AU 2018363292 A AU2018363292 A AU 2018363292A AU 2018363292 A AU2018363292 A AU 2018363292A AU 2018363292 A1 AU2018363292 A1 AU 2018363292A1
Authority
AU
Australia
Prior art keywords
seqid
seq
binding molecule
sequence
psma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2018363292A
Other languages
English (en)
Inventor
Verena BRUCKLACHER-WALDERT
Carolyn EDWARDS
James LEGG
Jayesh MAJITHIYA
Christine ROSSANT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Crescendo Biologics Ltd
Original Assignee
Crescendo Biologics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1718734.5A external-priority patent/GB201718734D0/en
Priority claimed from GBGB1718735.2A external-priority patent/GB201718735D0/en
Priority claimed from GBGB1808589.4A external-priority patent/GB201808589D0/en
Application filed by Crescendo Biologics Ltd filed Critical Crescendo Biologics Ltd
Publication of AU2018363292A1 publication Critical patent/AU2018363292A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2018363292A 2017-11-13 2018-11-13 Molecules that bind to CD137 and PSMA Abandoned AU2018363292A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB1718735.2 2017-11-13
GB1718734.5 2017-11-13
GBGB1718734.5A GB201718734D0 (en) 2017-11-13 2017-11-13 Single domain antibodies that bind to CD137
GBGB1718735.2A GB201718735D0 (en) 2017-11-13 2017-11-13 Bispecific molecules that bind to CD137 and PSMA
GBGB1808589.4A GB201808589D0 (en) 2018-05-24 2018-05-24 Single domain antibodies that bind CD137
GB1808589.4 2018-05-24
PCT/GB2018/053280 WO2019092452A1 (en) 2017-11-13 2018-11-13 Molecules that bind to cd137 and psma

Publications (1)

Publication Number Publication Date
AU2018363292A1 true AU2018363292A1 (en) 2020-05-21

Family

ID=64457031

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018363292A Abandoned AU2018363292A1 (en) 2017-11-13 2018-11-13 Molecules that bind to CD137 and PSMA
AU2018363291A Abandoned AU2018363291A1 (en) 2017-11-13 2018-11-13 Single domain antibodies that bind to CD137

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2018363291A Abandoned AU2018363291A1 (en) 2017-11-13 2018-11-13 Single domain antibodies that bind to CD137

Country Status (10)

Country Link
US (2) US12077595B2 (enExample)
EP (2) EP3710477A1 (enExample)
JP (3) JP2021502810A (enExample)
KR (2) KR20200083574A (enExample)
CN (4) CN111699197B (enExample)
AU (2) AU2018363292A1 (enExample)
CA (2) CA3082321A1 (enExample)
IL (2) IL274370A (enExample)
SG (2) SG11202003912RA (enExample)
WO (2) WO2019092452A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017122017A1 (en) 2016-01-12 2017-07-20 Crescendo Biologics Limited Therapeutic molecules
GB201607968D0 (en) 2016-05-06 2016-06-22 Crescendo Biolog Ltd Chimeric antigen receptor
WO2018127709A1 (en) 2017-01-06 2018-07-12 Crescendo Biologics Limited Single domain antibodies to programmed cell death (pd-1)
GB201711068D0 (en) * 2017-07-10 2017-08-23 Crescendo Biologics Ltd Therapeutic molecules binding PSMA
AU2018363292A1 (en) 2017-11-13 2020-05-21 Crescendo Biologics Limited Molecules that bind to CD137 and PSMA
GB201802573D0 (en) 2018-02-16 2018-04-04 Crescendo Biologics Ltd Therapeutic molecules that bind to LAG3
JP2020132572A (ja) * 2019-02-20 2020-08-31 旭化成株式会社 シラノール組成物、硬化物及び製造方法
CN113840835B (zh) * 2019-05-15 2024-06-25 克雷森多生物制剂有限公司 结合分子
EP3853257A4 (en) * 2019-08-12 2022-06-29 I-Mab Biopharma US Limited Anti-claudin 18.2 and anti-4-1bb bispecific antibodies and uses thereof
US20220411523A1 (en) * 2019-11-13 2022-12-29 Hefei Hankemab Biotechnology Co., Ltd Molecule capable of binding to human 4-1bb and its application thereof
JP2023502652A (ja) * 2019-11-18 2023-01-25 ヤンセン バイオテツク，インコーポレーテツド 抗ｃｄ７９キメラ抗原受容体、ｃａｒ－ｔ細胞、及びそれらの使用
EP4155319A4 (en) * 2020-06-30 2024-06-12 Nona Biosciences (Suzhou) Co., Ltd. 4-1BB BINDING PROTEIN AND ITS USE
CA3194771A1 (en) 2020-09-16 2022-03-24 Amgen Inc. Methods for administering therapeutic doses of bispecific t-cell engaging molecules for the treatment of cancer
CN114195894B (zh) * 2020-09-17 2025-02-25 普米斯生物技术(珠海)有限公司 一种靶向4-1bb的抗体及其应用
JP2024521701A (ja) * 2021-05-21 2024-06-04 ベイジーン スウィッツァーランド ゲーエムベーハー 抗ｃｄ１３７抗体及びその使用方法
WO2022242682A1 (en) * 2021-05-21 2022-11-24 Beigene, Ltd. Anti-gpc3 and anti-cd137 multispecific antibodies and methods of use
CN113621065B (zh) * 2021-08-30 2023-08-01 武汉海沙百得生物技术有限公司 靶向4-1bb的全人源抗体及其制备方法和应用
JP2024530325A (ja) * 2021-08-31 2024-08-16 ラノバ メディシンズ リミテッド 抗４－１ｂｂナノボディ
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
JP2025531938A (ja) * 2022-09-22 2025-09-25 アブリンク バイオテック カンパニー リミテッド 抗４－１ｂｂナノボディ、その製造及び使用
JP2025539145A (ja) * 2022-11-21 2025-12-03 ベイジン スウィッツアランド ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ｃｄ１３７抗体及びその使用方法
WO2024249954A1 (en) 2023-05-31 2024-12-05 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
JP2025022410A (ja) 2023-08-03 2025-02-14 ルネサスエレクトロニクス株式会社 半導体装置およびその製造方法
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
CN118629502A (zh) * 2024-06-19 2024-09-10 中山百灵生物技术股份有限公司 基于数据处理的核苷酸序列实验预测优化系统

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
WO2003034903A2 (en) 2001-10-23 2003-05-01 Psma Development Company, L.L.C. Psma antibodies and protein multimers
GB2398784B (en) 2003-02-26 2005-07-27 Babraham Inst Removal and modification of the immunoglobulin constant region gene cluster of a non-human mammal
GB0400440D0 (en) 2004-01-09 2004-02-11 Isis Innovation Receptor modulators
EP1753783B1 (en) * 2004-06-03 2014-08-06 Novimmune SA Anti-cd3 antibodies and methods of use thereof
GB0521621D0 (en) * 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
PL1851250T3 (pl) 2005-02-18 2012-10-31 Squibb & Sons Llc Ludzkie przeciwciało monoklonalne przeciwko antygenowi błony komórkowej komórek prostaty (PSMA)
WO2007117264A2 (en) 2005-08-03 2007-10-18 Fraunhofer Usa, Inc. Compositions and methods for production of immunoglobulins
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
US20110009453A1 (en) 2008-03-17 2011-01-13 Donello John E s1p3 receptor inhibitors for treating inflammation
US20100122358A1 (en) 2008-06-06 2010-05-13 Crescendo Biologics Limited H-Chain-only antibodies
CA2731216A1 (en) * 2008-07-18 2010-01-21 Oragenics, Inc. Compositions for the detection and treatment of colorectal cancer
MX2011003195A (es) 2008-09-26 2011-08-12 Dana Farber Cancer Inst Inc Anticuerpos anti-pd-1, pd-l1 y pd-l2 humanos y usos de los mismos.
US9120855B2 (en) * 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
US20130202623A1 (en) 2010-02-16 2013-08-08 Nicolas Chomont Pd-1 modulation and uses thereof for modulating hiv replication
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
JP2014501515A (ja) 2010-12-01 2014-01-23 グラクソ グループ リミテッド 改良された抗血清アルブミン結合単一可変ドメイン
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
CN104159909A (zh) 2012-02-22 2014-11-19 宾夕法尼亚大学董事会 产生用于癌症治疗的t细胞持续性群体的组合物和方法
US20130302250A1 (en) 2012-05-07 2013-11-14 The University Court Of The University Of Aberdeen Single domain binding molecule
JP6411333B2 (ja) * 2012-05-24 2018-10-24 ブイアイビー ブイゼットダブリュＶｉｂ Ｖｚｗ 腫瘍関連マクロファージのターゲティングおよびｉｎｖｉｖｏイメージング用抗マクロファージマンノース受容体単一可変ドメイン
CN103087171B (zh) 2012-12-24 2015-01-14 中国人民解放军第四军医大学 一种用于前列腺癌早期诊断和治疗的抗psma/fitc双特异性抗体及其制备方法
US10993420B2 (en) 2013-03-15 2021-05-04 Erasmus University Medical Center Production of heavy chain only antibodies in transgenic mammals
CN103333249A (zh) 2013-06-14 2013-10-02 广州康合生物科技有限公司 一种抗前列腺特异性膜抗原（psma）的单克隆抗体及其应用
JP6417419B2 (ja) 2013-09-04 2018-11-07 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 免疫調節剤として有用な化合物
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
KR20150089702A (ko) 2014-01-28 2015-08-05 제일모직주식회사 신규 화합물, 신규 폴리머, 이를 포함하는 착색제, 이를 포함하는 감광성 수지 조성물 및 컬러필터
HRP20212033T1 (hr) 2014-01-28 2022-04-01 Bristol-Myers Squibb Company Anti-lag-3 antitijela za liječenje hematoloških maligniteta
EP3593812A3 (en) 2014-03-15 2020-05-27 Novartis AG Treatment of cancer using chimeric antigen receptor
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
CA2943943C (en) * 2014-04-07 2023-01-10 Chugai Seiyaku Kabushiki Kaisha Immunoactivating antigen-binding molecule
MX380358B (es) 2014-04-25 2025-03-12 Pf Medicament Anticuerpo igf-1r y su uso como un vehiculo con especificidad de objetivo para el tratamiento contra el cancer.
US10092645B2 (en) * 2014-06-17 2018-10-09 Medimmune Limited Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
DK3177644T3 (da) 2014-08-05 2021-01-11 MabQuest SA Immunologiske reagenser, som binder til PD-1
AU2015301460B2 (en) 2014-08-14 2021-04-08 Novartis Ag Treatment of cancer using GFR alpha-4 chimeric antigen receptor
SG11201702502XA (en) 2014-10-22 2017-05-30 Crescendo Biolog Ltd Transgenic mice
WO2016073760A1 (en) 2014-11-05 2016-05-12 The Regents Of The University Of California Methods for stratifying non-responders to therapies that block pd1/pdl1 axis
CA2971734C (en) 2014-12-22 2025-11-18 Enumeral Biomedical Holdings Inc Anti-pd-1 antibodies
WO2016177802A1 (en) 2015-05-04 2016-11-10 Pieris Pharmaceuticals Gmbh Anti-cancer fusion polypeptide
RU2754466C2 (ru) * 2015-05-18 2021-09-02 ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ Слитый полипептид с противораковой активностью
CN105061597B (zh) 2015-06-09 2016-04-27 北京东方百泰生物科技有限公司 一种抗pd-1的单克隆抗体及其获得方法
SMT202100527T1 (it) 2015-07-30 2021-11-12 Macrogenics Inc Molecole di legame a pd-1 e lag-3 e loro metodi d'uso
CN106397592A (zh) 2015-07-31 2017-02-15 苏州康宁杰瑞生物科技有限公司 针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
JP7074665B2 (ja) * 2015-10-07 2022-05-24 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 共刺激ｔｎｆ受容体に対する四価の二重特異性抗体発明の分野
MA43260A (fr) 2015-11-18 2018-09-26 Merck Sharp & Dohme Liants pd1 et/ou lag3
SG10201912405TA (en) * 2016-01-11 2020-02-27 Inhibrx Inc Multivalent and multispecific 41bb-binding fusion proteins
WO2017122017A1 (en) 2016-01-12 2017-07-20 Crescendo Biologics Limited Therapeutic molecules
CN105968205B (zh) 2016-02-03 2019-04-26 中国人民解放军第三军医大学第三附属医院 一种抗前列腺特异性膜抗原的纳米抗体
CN105968204B (zh) 2016-02-03 2020-01-21 中国人民解放军第三军医大学第一附属医院 一种抗前列腺特异性膜抗原的单域重链抗体
CN105968203A (zh) 2016-02-03 2016-09-28 南昌大学 一种抗前列腺特异性膜抗原胞外区的单域重链抗体
WO2017182672A1 (en) * 2016-04-22 2017-10-26 Alligator Bioscience Ab Novel bispecific polypeptides against cd137
GB201607968D0 (en) 2016-05-06 2016-06-22 Crescendo Biolog Ltd Chimeric antigen receptor
IL263102B2 (en) 2016-05-20 2023-11-01 Harpoon Therapeutics Inc A serum albumin-binding protein with a single site
BR112018074453A2 (pt) * 2016-05-27 2019-03-19 Abbvie Biotherapeutics Inc. proteínas de ligação biespecíficas ligando uma protéina imunomoduladora e um antígeno tumoral
RU2022101604A (ru) 2016-12-07 2022-03-29 Аблинкс Нв Улучшенные отдельные вариабельные домены иммуноглобулина, связывающиеся с сывороточным альбумином
CN107674122A (zh) 2016-12-28 2018-02-09 天津天锐生物科技有限公司 一种识别人血清白蛋白的单域抗体
WO2018127709A1 (en) 2017-01-06 2018-07-12 Crescendo Biologics Limited Single domain antibodies to programmed cell death (pd-1)
CN110520157A (zh) 2017-02-09 2019-11-29 纪念斯隆凯特琳癌症中心 抗-kir3dl1抗体
WO2018224439A1 (en) 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-hsa antibodies
EP3425763B1 (en) 2017-07-03 2020-11-18 France Brevets Coupling interface and method of operation
AU2018297061B2 (en) 2017-07-06 2021-05-06 Merus N.V. Antibodies that modulate a biological activity expressed by a cell
GB201711068D0 (en) 2017-07-10 2017-08-23 Crescendo Biologics Ltd Therapeutic molecules binding PSMA
WO2019072868A1 (en) * 2017-10-10 2019-04-18 Numab Therapeutics AG MULTISPECIFIC ANTIBODIES
EP3470426A1 (en) 2017-10-10 2019-04-17 Numab Therapeutics AG Multispecific antibody
AU2018363292A1 (en) 2017-11-13 2020-05-21 Crescendo Biologics Limited Molecules that bind to CD137 and PSMA
GB201802573D0 (en) 2018-02-16 2018-04-04 Crescendo Biologics Ltd Therapeutic molecules that bind to LAG3
GB201818460D0 (en) 2018-11-13 2018-12-26 Crescendo Biologics Ltd Single domain antibodies that bind human serum albumin
CN113840835B (zh) 2019-05-15 2024-06-25 克雷森多生物制剂有限公司 结合分子

Also Published As

Publication number Publication date
US20200362047A1 (en) 2020-11-19
CN111683968B (zh) 2024-07-05
WO2019092451A1 (en) 2019-05-16
CN118667027A (zh) 2024-09-20
CA3082321A1 (en) 2019-05-16
JP2021502104A (ja) 2021-01-28
CA3082297A1 (en) 2019-05-16
SG11202003912RA (en) 2020-05-28
US20200362051A1 (en) 2020-11-19
JP7312168B2 (ja) 2023-07-20
IL274371A (en) 2020-06-30
CN111699197B (zh) 2024-08-23
IL274370A (en) 2020-06-30
EP3710477A1 (en) 2020-09-23
EP3710478A1 (en) 2020-09-23
KR20200083574A (ko) 2020-07-08
CN111699197A (zh) 2020-09-22
US12077595B2 (en) 2024-09-03
CN111683968A (zh) 2020-09-18
CN118955716A (zh) 2024-11-15
KR20200080304A (ko) 2020-07-06
WO2019092452A1 (en) 2019-05-16
SG11202003978UA (en) 2020-05-28
AU2018363291A1 (en) 2020-05-21
JP2023126951A (ja) 2023-09-12
JP2021502810A (ja) 2021-02-04

Similar Documents

Publication Publication Date Title
US20200362051A1 (en) Molecules that bind to cd137 and psma
JP7499813B2 (ja) 腫瘍壊死因子 （ｔｎｆ） スーパーファミリー受容体結合分子およびその使用
CN110036032B (zh) 抗muc16(粘蛋白16)抗体
KR102587941B1 (ko) 향상된 효능작용 및 이펙터 기능을 갖는 조작된 항체 및 다른 Fc-도메인 함유 분자
JP6515101B2 (ja) Ｇｉｔｒ抗原結合タンパク質
JP6794348B2 (ja) ヒト化抗ｏｘ４０抗体及びその使用
WO2018127711A1 (en) Single Domain Antibodies to Programmed Cell Death (PD-1)
JP2022504802A (ja) ５ｔ４シングルドメイン抗体およびその治療組成物
CN109641037A (zh) 抗psma抗体及其用途
WO2019184909A1 (zh) 新型抗体分子、其制备方法及其用途
US20220220215A1 (en) Binding molecules
CN113631571B (zh) 抗骨膜蛋白抗体及其用途
US20240002530A1 (en) Anti-psma antibodies and methods of use
KR20230079074A (ko) 면역글로불린 ｅ 항체 조성물 및 사용 방법
WO2024188272A1 (zh) Trop2单域抗体、融合蛋白及其应用
WO2023173393A1 (zh) 结合b7-h3的抗体及其用途

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ BRUCKLACHER-WALDERT, VERENA; EDWARDS, CAROLYN; LEGG, JAMES; MAJITHIYA, JAYESH AND ROSSANT, CHRISTINE

MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted